Rezultati - Lisa Sproat

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

    CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo od Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Andrew McNally, Ivana Gojo, Judith E. Karp, Ruben A. Mesa, Lisa Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Genetic features and clinical outcomes of patients with isolated and comutated<i>DDX41</i>-mutated myeloid neoplasms

    Genetic features and clinical outcomes of patients with isolated and comutated<i>DDX41</i>-mutated myeloid neoplasms od Hassan B. Alkhateeb, Ahmad Nanaa, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Sproat, Rong He, Phuong L. Nguyen, Dragan Jevremović, Mohamad E. Salama, Patricia T. Greipp, Naseema Gangat, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun Vinod Shah, Mrinal M. Patnaik, Aref Al‐Kali

    Izdano 2021
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

    Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients od Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla McKerrow Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi

    Izdano 2023
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

    Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and sur... od Omer Karrar, Maymona Abdelmagid, Masooma Shifa Rana, Moazah Iftikhar, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

    Izdano 2023
    Polni tekst Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations

    Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations od Anmol Baranwal, Kimberly J. Langer, Vedavyas Gannamani, Danielle Rud, Alia Cibich, Caner Saygin, Mariam T. Nawas, Talha Badar, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, Vivek Roy, James M. Foran, Hemant S. Murthy, Madiha Iqbal, Jeanne Palmer, Lisa Sproat, Saurabh Chhabra, Nandita Khera, Mehrdad Hefazi, Abhishek A. Mangaonkar, William J. Hogan, Mark R. Litzow, Hassan B. Alkhateeb, Ayalew Tefferi, Chung Hoow Kok, Guru Subramanian Guru Murthy, Anand Patel, Ashish Bajel, Devendra Hiwase, Mithun Vinod Shah

    Izdano 2025
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent

    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent od Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna, Isla McKerrow Johnson, Maymona Abdelmagid, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek A. Mangaonkar, Aasiya Matin, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Samuel J. Yates, Abigail Sneider, Emily Dworkin, Anand Patel, Alexandre Bazinet, Jayastu Senapati, Álex Bataller, Courtney D. DiNardo, Tapan M. Kadia, Ayalew Tefferi

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: